211 related articles for article (PubMed ID: 34341902)
21. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
[TBL] [Abstract][Full Text] [Related]
22. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
[TBL] [Abstract][Full Text] [Related]
23. Correlation between outcome and extent of residual disease in the sentinel node after neoadjuvant chemotherapy in clinically fine-needle proven node-positive breast cancer patients.
Canavese G; Tinterri C; Carli F; Garrone E; Spinaci S; Della Valle A; Barbieri E; Marrazzo E; Bruzzi P; Dozin B
Eur J Surg Oncol; 2021 Aug; 47(8):1920-1927. PubMed ID: 33972144
[TBL] [Abstract][Full Text] [Related]
24. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
[TBL] [Abstract][Full Text] [Related]
25. A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study.
van Nijnatten TJA; Simons JM; Smidt ML; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef K; Koppert LB; Luiten EJT
Clin Breast Cancer; 2017 Aug; 17(5):399-402. PubMed ID: 28487053
[TBL] [Abstract][Full Text] [Related]
26. Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed?
Baker JL; Muhsen S; Zabor EC; Stempel M; Gemignani ML
Ann Surg Oncol; 2019 Feb; 26(2):336-342. PubMed ID: 30506175
[TBL] [Abstract][Full Text] [Related]
27. Intraoperative assessment of sentinel lymph node by one-step nucleic acid amplification in breast cancer patients after neoadjuvant treatment reduces the need for a second surgery for axillary lymph node dissection.
Espinosa-Bravo M; Navarro-Cecilia J; Ramos Boyero M; Diaz-Botero S; Dueñas Rodríguez B; Luque López C; Ramos Grande T; Ruano Perez R; Peg V; Rubio IT
Breast; 2017 Feb; 31():40-45. PubMed ID: 27810698
[TBL] [Abstract][Full Text] [Related]
28. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH
Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791
[TBL] [Abstract][Full Text] [Related]
29. Preoperative Prediction of Node-Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node-Negative or Node-Positive Breast Cancer.
Murphy BL; L Hoskin T; Heins CDN; Habermann EB; Boughey JC
Ann Surg Oncol; 2017 Sep; 24(9):2518-2525. PubMed ID: 28484921
[TBL] [Abstract][Full Text] [Related]
30. Sentinel lymph node biopsy using periareolar injection of radiocolloid for patients with neoadjuvant chemotherapy-treated breast carcinoma.
Shimazu K; Tamaki Y; Taguchi T; Akazawa K; Inoue T; Noguchi S
Cancer; 2004 Jun; 100(12):2555-61. PubMed ID: 15197796
[TBL] [Abstract][Full Text] [Related]
31. Axillary sentinel node biopsy after neoadjuvant chemotherapy.
Ozmen V; Unal ES; Muslumanoglu ME; Igci A; Canbay E; Ozcinar B; Mudun A; Tunaci M; Tuzlali S; Kecer M
Eur J Surg Oncol; 2010 Jan; 36(1):23-9. PubMed ID: 19931375
[TBL] [Abstract][Full Text] [Related]
32. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
[TBL] [Abstract][Full Text] [Related]
33. Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?
Moo TA; Edelweiss M; Hajiyeva S; Stempel M; Raiss M; Zabor EC; Barrio A; Morrow M
Ann Surg Oncol; 2018 Jun; 25(6):1488-1494. PubMed ID: 29572705
[TBL] [Abstract][Full Text] [Related]
34. Combined procedure of marking axillary positive node with iodine-125 seed and sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy.
Custodio Rebollo Aguirre A; Sánchez Sánchez R; González Jiménez AD; Culiañez Casas M; Mendoza Arnau I; Rashki M; Rudolphi Solero T; Martínez Meca S
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(2):75-83. PubMed ID: 31759957
[TBL] [Abstract][Full Text] [Related]
35. Improved False-Negative Rates with Intraoperative Identification of Clipped Nodes in Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy.
Cabıoğlu N; Karanlık H; Kangal D; Özkurt E; Öner G; Sezen F; Yılmaz R; Tükenmez M; Önder S; İğci A; Özmen V; Dinççağ A; Engin G; Müslümanoğlu M
Ann Surg Oncol; 2018 Oct; 25(10):3030-3036. PubMed ID: 29978371
[TBL] [Abstract][Full Text] [Related]
36. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance).
Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton TS; Kuerer HM; Bowling M; Hunt KK;
Ann Surg; 2015 Mar; 261(3):547-52. PubMed ID: 25664534
[TBL] [Abstract][Full Text] [Related]
37. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
Breslin TM; Cohen L; Sahin A; Fleming JB; Kuerer HM; Newman LA; Delpassand ES; House R; Ames FC; Feig BW; Ross MI; Singletary SE; Buzdar AU; Hortobagyi GN; Hunt KK
J Clin Oncol; 2000 Oct; 18(20):3480-6. PubMed ID: 11032588
[TBL] [Abstract][Full Text] [Related]
38. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer.
Kida K; Ishikawa T; Yamada A; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
Eur J Surg Oncol; 2015 Apr; 41(4):566-70. PubMed ID: 25650249
[TBL] [Abstract][Full Text] [Related]
39. Review of Novel Sentinel Lymph Node Biopsy Techniques in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Ersoy YE; Kadioglu H
Clin Breast Cancer; 2018 Aug; 18(4):e555-e559. PubMed ID: 29429940
[TBL] [Abstract][Full Text] [Related]
40. Is Clinical Exam of the Axilla Sufficient to Select Node-Positive Patients Who Downstage After NAC for SLNB? A Comparison of the Accuracy of Clinical Exam Versus MRI.
Moo TA; Jochelson MS; Zabor EC; Stempel M; Raiss M; Mamtani A; Tadros AB; El-Tamer M; Morrow M
Ann Surg Oncol; 2019 Dec; 26(13):4238-4243. PubMed ID: 31583546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
